In recent years, neuroinflammation has attracted particular interest; increased risk of developing AD and cognitive decline is associated with genetic variants of molecules associated with ‘‘microgliopathies’’, including the 12 kDa DNAX activating protein (DAP12) and the triggering receptor expressed in myeloid cells-2 (TREM2) in Nasu-Hakola disease (NHD) [10,11,12]. The gene discussed is TREM2; the disease is Alzheimer disease.